<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="21534"><DrugName>navitoclax</DrugName><DrugNamesKey><Name id="42924125">navitoclax</Name><Name id="43032209">navitoclax dihydrochloride</Name></DrugNamesKey><DrugSynonyms><Name><Value>A-317267</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>A-371191</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>A-385358</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>A-438744</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Bax modulators (anticancer), Idun/Abbott</Value></Name><Name><Value>Bcl-2/Bcl-xL inhibitors (anticancer), Abbott/Idun</Value></Name><Name><Value>cancer therapeutics (Bcl-2/Bcl-xL inhibitors), Abbott/Idun</Value></Name><Name><Value>Bax modulators (anticancer, oral), Abbott</Value></Name><Name><Value>Bcl-2/Bcl-xL inhibitors (anticancer), Abbott</Value></Name><Name><Value>cancer therapeutics (Bcl-2/Bcl-xL inhibitors), Abbott</Value></Name><Name><Value>ABT-263</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>navitoclax</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>RG-7433</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>navitoclax dihydrochloride</Value><Types><Type>USAN</Type></Types></Name><Name><Value>A-855071.0</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>923564-51-6</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>1093851-28-5</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="13601">Abbott Laboratories</CompanyOriginator><CompaniesSecondary><Company id="1072507">AbbVie Inc</Company><Company id="13601">Abbott Laboratories</Company><Company id="19453">Genentech Inc</Company><Company id="24182">Idun Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="21534" type="Drug"><TargetEntity id="474044" type="siDrug">Navitoclax</TargetEntity></SourceEntity><SourceEntity id="1072507" type="Company"><TargetEntity id="5037613143" type="organizationId">AbbVie Inc</TargetEntity></SourceEntity><SourceEntity id="13601" type="Company"><TargetEntity id="4295903265" type="organizationId">Abbott Laboratories</TargetEntity></SourceEntity><SourceEntity id="19453" type="Company"><TargetEntity id="4295912132" type="organizationId">Genentech Inc</TargetEntity></SourceEntity><SourceEntity id="24182" type="Company"><TargetEntity id="4297216754" type="organizationId">IDUN Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1261" type="ciIndication"><TargetEntity id="10041056" type="MEDDRA"></TargetEntity><TargetEntity id="D055752" type="MeSH"></TargetEntity><TargetEntity id="70573" type="ORPHANET"></TargetEntity><TargetEntity id="-1257831198" type="omicsDisease"></TargetEntity><TargetEntity id="614" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"></TargetEntity><TargetEntity id="D002289" type="MeSH"></TargetEntity><TargetEntity id="-1730468577" type="omicsDisease"></TargetEntity><TargetEntity id="612" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1734" type="ciIndication"><TargetEntity id="10008958" type="MEDDRA"></TargetEntity><TargetEntity id="690" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1749" type="ciIndication"><TargetEntity id="C83.3" type="ICD10"></TargetEntity><TargetEntity id="10012818" type="MEDDRA"></TargetEntity><TargetEntity id="D016403" type="MeSH"></TargetEntity><TargetEntity id="544" type="ORPHANET"></TargetEntity><TargetEntity id="-308083648" type="omicsDisease"></TargetEntity><TargetEntity id="1741" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="203" type="ciIndication"><TargetEntity id="10025310" type="MEDDRA"></TargetEntity><TargetEntity id="D008223" type="MeSH"></TargetEntity><TargetEntity id="-386134440" type="omicsDisease"></TargetEntity><TargetEntity id="698" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2054" type="ciIndication"><TargetEntity id="10066476" type="MEDDRA"></TargetEntity><TargetEntity id="D019337" type="MeSH"></TargetEntity><TargetEntity id="-105358819" type="omicsDisease"></TargetEntity><TargetEntity id="1328" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2404" type="ciIndication"><TargetEntity id="10025140" type="MEDDRA"></TargetEntity><TargetEntity id="D008181" type="MeSH"></TargetEntity><TargetEntity id="-329641834" type="omicsDisease"></TargetEntity><TargetEntity id="340" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="55155" type="Action"><TargetEntity id="3112" type="Mechanism">Bcl-w Inhibitors</TargetEntity></SourceEntity><SourceEntity id="14541" type="Action"><TargetEntity id="1813" type="Mechanism">Bcl-xl Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity><SourceEntity id="16111" type="Action"><TargetEntity id="1812" type="Mechanism">Bcl-2 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-03718" type="ciTarget"><TargetEntity id="15949580545723" type="siTarget">Bcl2-associated agonist of cell death</TargetEntity><TargetEntity id="71" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-09919" type="ciTarget"><TargetEntity id="3037038525993" type="siTarget">Bcl-2-like protein 2</TargetEntity><TargetEntity id="9109" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="1261">Small-cell lung cancer</Indication><Indication id="1262">Non-small-cell lung cancer</Indication><Indication id="1734">Chronic lymphocytic leukemia</Indication><Indication id="1749">Diffuse large B-cell lymphoma</Indication><Indication id="203">Lymphoma</Indication><Indication id="2054">Hematological neoplasm</Indication><Indication id="2404">Lupus nephritis</Indication><Indication id="651">Cancer</Indication><Indication id="725">Solid tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="55155">Apoptosis regulator Bcl w inhibitor</Action><Action id="14541">Bcl-xL Bcl-2 associated death promotor inhibitor</Action><Action id="16111">Bcl-2 protein inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="1589">Apoptosis stimulator</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology></Technologies><LastModificationDate>2018-07-23T05:09:05.000Z</LastModificationDate><ChangeDateLast>2018-10-22T00:00:00.000Z</ChangeDateLast><AddedDate>1999-01-13T13:56:06.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1072507" linkType="Company"&gt;AbbVie&lt;/ulink&gt;, following its spin-out from &lt;ulink linkID="13601" linkType="Company"&gt;Abbott&lt;/ulink&gt;  in January 2013 [&lt;ulink linkID="1353481" linkType="Reference"&gt;1353481&lt;/ulink&gt;], [&lt;ulink linkID="1353488" linkType="Reference"&gt;1353488&lt;/ulink&gt;], was developing navitoclax (ABT-263; RG-7433; A-855071.0; structure shown), the lead from a series of small molecule  Bcl-2/Bcl-xL/Bcl-w inhibitors,  for the potential oral treatment of cancer [&lt;ulink linkID="311280" linkType="reference"&gt;311280&lt;/ulink&gt;], [&lt;ulink linkID="265668" linkType="reference"&gt;265668&lt;/ulink&gt;], [&lt;ulink linkID="554809" linkType="Reference"&gt;554809&lt;/ulink&gt;], [&lt;ulink linkID="398274" linkType="reference"&gt;398274&lt;/ulink&gt;], [&lt;ulink linkID="464407" linkType="reference"&gt;464407&lt;/ulink&gt;], [&lt;ulink linkID="983719" linkType="Reference"&gt;983719&lt;/ulink&gt;], [&lt;ulink linkID="1027961" linkType="Reference"&gt;1027961&lt;/ulink&gt;], [&lt;ulink linkID="1177394" linkType="Reference"&gt;1177394&lt;/ulink&gt;], [&lt;ulink linkID="1676404" linkType="Reference"&gt;1676404&lt;/ulink&gt;]. By November 2006, the drug was in a phase I/II study for relapsed or refractory lymphoma  [&lt;ulink linkID="739334" linkType="Reference"&gt;739334&lt;/ulink&gt;], [&lt;ulink linkID="745104" linkType="Reference"&gt;745104&lt;/ulink&gt;]; in June 2011, preliminary phase II data were presented [&lt;ulink linkID="1198165" linkType="Reference"&gt;1198165&lt;/ulink&gt;], [&lt;ulink linkID="1199398" linkType="Reference"&gt;1199398&lt;/ulink&gt;].  In March 2007, a phase I/IIa study in small-cell lung cancer (SCLC) patients was initiated [&lt;ulink linkID="794585" linkType="Reference"&gt;794585&lt;/ulink&gt;];  in June 2010, data from the phase IIa portion were presented  [&lt;ulink linkID="1104623" linkType="Reference"&gt;1104623&lt;/ulink&gt;]. In June 2007, a phase I/II trial in chronic lymphocytic leukemia (CLL) began [&lt;ulink linkID="985667" linkType="Reference"&gt;985667&lt;/ulink&gt;], and by October 2009, the phase II portion had been initiated [&lt;ulink linkID="1049733" linkType="Reference"&gt;1049733&lt;/ulink&gt;]; in June 2011, results were presented [&lt;ulink linkID="1197327" linkType="Reference"&gt;1197327&lt;/ulink&gt;]. By October 2011, the drug was in phase II development for non-small-cell lung cancer (NSCLC) [&lt;ulink linkID="1242860" linkType="Reference"&gt;1242860&lt;/ulink&gt;]. By March 2013, AbbVie had discontinued development of ABT-263 [&lt;ulink linkID="1498723" linkType="Reference"&gt;1498723&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The drug was previously being investigated for the potential treatment of diffuse large B-cell lymphoma, however a phase II study in this setting was withdrawn in June 2012 prior to enrollment [&lt;ulink linkID="1323937" linkType="Reference"&gt;1323937&lt;/ulink&gt;]. AbbVie was also investigating navitoclax for the potential treatment of lupus nephritis; in June 2013, preclinical data  were presented [&lt;ulink linkID="1441913" linkType="Reference"&gt;1441913&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="19453" linkType="Company"&gt;Genentech&lt;/ulink&gt; (a wholly owned subsidiary of &lt;ulink linkID="19446" linkType="Company"&gt;Roche&lt;/ulink&gt;)  was previously collaborating with Abbott in the development of navitoclax [&lt;ulink linkID="808616" linkType="Reference"&gt;808616&lt;/ulink&gt;]. By February 2012, however, rights had been returned to Abbott [&lt;ulink linkID="1259334" linkType="Reference"&gt;1259334&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Previous leads have included  &lt;ulink linkID="66368" linkType="Drug"&gt;ABT-737&lt;/ulink&gt;, A-385358 and A-317267  [&lt;ulink linkID="494551" linkType="reference"&gt;494551&lt;/ulink&gt;]. Abbott was  investigating the series with &lt;ulink linkID="24182" linkType="Company"&gt;Idun Pharmaceuticals&lt;/ulink&gt; until December 2003, at which point, the collaboration was concluded  and Abbott  continued clinical development of the compounds [&lt;ulink linkID="596648" linkType="Reference"&gt;596648&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Lymphoid malignancies&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In November 2006, a non-randomized, open-label, uncontrolled phase I/II trial (&lt;ulink linkID="40093" linkType="Protocol"&gt;NCT00406809&lt;/ulink&gt;, M06-814) was underway in subjects (expected n = 110) with relapsed or refractory lymphoid malignancies in the US.  The subjects were to receive either a   repeating sequence of 14 days on therapy and 7 days off, or   continuous dosing until disease progression. Primary endpoints were an evaluation of pharmacokinetics, determination of the MTD and  associated biomarkers. The trial was  expected to complete in June 2010 [&lt;ulink linkID="745104" linkType="Reference"&gt;745104&lt;/ulink&gt;], [&lt;ulink linkID="985616" linkType="Reference"&gt;985616&lt;/ulink&gt;]. In May 2009, data  presented at the 45th ASCO meeting in Orlando, FL, showed that  pharmacokinetics were linear with a terminal half-life of 14 to 20 h. Of 40 patients, 3 had a partial response and 1 showed minor response. Of 16 patients receiving continuous dosing,   3 showed a &amp;gt;/= 50% decrease in lymphocytes and 1 had an unconfirmed partial response. DLTs reported were thrombocytopenia and  elevated levels of alanine transaminases with    315 mg of navitoclax for 14days  [&lt;ulink linkID="1009438" linkType="Reference"&gt;1009438&lt;/ulink&gt;]. In December 2009, data were presented at the 51st ASH meeting in New Orleans, LA. Of 43 patients evaluable for response, 8 showed over 50% tumor regression.  Dose escalation was ongoing [&lt;ulink linkID="1058958" linkType="Reference"&gt;1058958&lt;/ulink&gt;]. In 1Q10, the phase IIa portion of the trial began [&lt;ulink linkID="1074105" linkType="Reference"&gt;1074105&lt;/ulink&gt;]. In June 2010, similar data were presented at the 15th EHA meeting in Barcelona, Spain. The phase II recommended dosing regimen was 150 mg 7-day lead-in followed by 325 mg/d continuous dosing [&lt;ulink linkID="1117897" linkType="Reference"&gt;1117897&lt;/ulink&gt;]. In March 2011, data from the phase I part of the study were presented at the 241st ACS meeting in Anaheim, CA. In a 62-year old female with small lymphocytic leukemia (SLL)/ CLL previously treated with &lt;ulink linkID="6156" linkType="Drug"&gt;fludarabine&lt;/ulink&gt;/ &lt;ulink linkID="6736" linkType="Drug"&gt;rituximab&lt;/ulink&gt;, a 99% total tumor reduction was observed after eight cycles  of treatment with navitoclax [&lt;ulink linkID="1174495" linkType="Reference"&gt;1174495&lt;/ulink&gt;]. In June 2011, preliminary phase II data were presented at the 16th EHA meeting in London, UK. Patients with CLL (n = 6) and small lymphocytic leukemia (n = 2) showed the best tumor responses and median PFS with the monotherapy. Of these eight patients, seven had a reduction in absolute lymphocyte count of more than 50%. It was recommended that in other tumor types, navitoclax should be tested in combination with other agents [&lt;ulink linkID="1198165" linkType="Reference"&gt;1198165&lt;/ulink&gt;], [&lt;ulink linkID="1199398" linkType="Reference"&gt;1199398&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In April 2009, a non-randomized, open-label phase I trial (&lt;ulink linkID="35488" linkType="Protocol"&gt;NCT00788684&lt;/ulink&gt;, M10-166) was initiated in patients (expected n = 24) with CD20-positive relapsed or refractory lymphoid malignancies in the US and Australia. The patients were to receive a once daily dosing of navitoclax until disease progression  in combination with a weekly iv infusion  of &lt;ulink linkID="6736" linkType="Drug"&gt;rituximab&lt;/ulink&gt; for four doses. The primary endpoint was a determination of dose limiting toxicity  (DLT) and maximum tolerated dose (MTD) when ABT is administered in combination with rituximab. The trial was expected to be completed in December 2010 [&lt;ulink linkID="985644" linkType="Reference"&gt;985644&lt;/ulink&gt;]. In June 2010, data were presented at the 15th Congress of the European Hematology Association in Barcelona, Spain.  Patients (n = 11) received 200 or 250mg navitoclax continuously per day plus rituximab (375mg/m2). The combination was well tolerated, and stable disease was reported in the 200 mg cohort. The MTD was not reached and accrual was ongoing in an expanded cohort to assess the recommended phase II dose [&lt;ulink linkID="1118973" linkType="Reference"&gt;1118973&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Chronic lymphocytic leukemia&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In February 2010, a randomized, phase II trial (ABT4710n; FRANC) was expected to begin in the first half of 2010 in patients (expected n = 120) with front-line CLL. Subjects would receive &lt;ulink linkID="6736" linkType="Drug"&gt;rituximab&lt;/ulink&gt; alone, rituximab plus navitoclax for 12 weeks, or rituximab plus navitoclax until progression, relapse or unacceptable toxicity is observed [&lt;ulink linkID="1074105" linkType="Reference"&gt;1074105&lt;/ulink&gt;], [&lt;ulink linkID="1139639" linkType="Reference"&gt;1139639&lt;/ulink&gt;]. In July 2010, this trial was expected to begin in the third quarter of 2010 [&lt;ulink linkID="1118196" linkType="Reference"&gt;1118196&lt;/ulink&gt;]. In December 2012, data were presented at the 54th ASH Annual meeting in Atlanta, GA. Patients received rituximab alone (375 and 500 mg/m2 qw; arm A; n = 40), rituximab + navitoclax (250 mg qd; arm B; n = 38) and rituximab + navitoclax (250 mg qd until disease progression; arm C; n = 40).   The overall response rates (ORR)  in the arms A, B, and C were 35, 55, and 70%, respectively; among patients with del(17p), in the arms A (n = 11), B (n = 11), and C (n = 10), the ORRs were 18%, 73%, and 60%, respectively; The progression-free survival in the arm C was longer than  the other arms. At that time, navitoclax development for CLL was discontinued due the promising data of &lt;ulink linkID="70895" linkType="Drug"&gt;ABT-199&lt;/ulink&gt; for CLL [&lt;ulink linkID="1347966" linkType="Reference"&gt;1347966&lt;/ulink&gt;].     &lt;/para&gt;&lt;para&gt;In June 2007, a non-randomized, open-label, uncontrolled phase I/II trial (&lt;ulink linkID="45749" linkType="Protocol"&gt;NCT00481091&lt;/ulink&gt;, M06-873) was initiated in patients (expected n = 72) with relapsed or refractory CLL in the US, Australia and Germany. Primary endpoints were a determination of DLT and MTD using two different dosing schedules, followed by an  additional safety assessment at the defined recommended dose. The trial was expected to be completed in June 2010 [&lt;ulink linkID="985667" linkType="Reference"&gt;985667&lt;/ulink&gt;]. In May 2009, clinical data presented at the 45th ASCO meeting in Orlando, FL, showed that  pharmacokinetics were linear  with a terminal half-life of 14 to 20 h. Of 27  patients, 3 had a partial response, 2 showed unconfirmed regression, 6 showed  a   &amp;gt;/= 50% decrease in lymphocytes and 11 had stable disease. DLT reported was bronchitis with 160 mg of navitoclax for 14 days  [&lt;ulink linkID="1009438" linkType="Reference"&gt;1009438&lt;/ulink&gt;]. By October 2009, the phase IIa portion had been initiated [&lt;ulink linkID="1049733" linkType="Reference"&gt;1049733&lt;/ulink&gt;]. In June 2011, interim phase II results were presented at the 16th EHA meeting in London, UK. Of 27 patients evaluable for response, a partial response was achieved in nine patients, stable disease in 17 patients, and disease progression in one patient. Patients with an isolated 11q deletion (n = 6) had a favorable outcome relative to those with a 17p deletion (n = 5) or normal cytogenetics (n = 6) [&lt;ulink linkID="1197327" linkType="Reference"&gt;1197327&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In August 2016, clinical data from phase I study were presented at the 24th EFMC-ISMC Symposium in Manchester, UK. Navitoclax showed single agent activity in CLL and lymphoma and concentration dependent thrombocytopenia [&lt;ulink linkID="1791731" linkType="Reference"&gt;1791731&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2009, a non-randomized, open-label, dose-escalating, phase Ib trial (&lt;ulink linkID="49908" linkType="Protocol"&gt;NCT00868413&lt;/ulink&gt;, M10-458) was planned in subjects (expected n = 36) with relapsed or refractory CLL. The patients were to receive  navitoclax daily for 3 days in combination with either &lt;ulink linkID="6156" linkType="Drug"&gt;fludarabine&lt;/ulink&gt;/&lt;ulink linkID="52332" linkType="Drug"&gt;cyclophosphamide&lt;/ulink&gt;/&lt;ulink linkID="6736" linkType="Drug"&gt;rituximab&lt;/ulink&gt; (FCR) or &lt;ulink linkID="47000" linkType="Drug"&gt;bendamustine&lt;/ulink&gt;/rituximab (BR). Primary endpoints would be safety, pharmacokinetics, determination of MTD  and recommended phase II dose. The trial was expected to complete in January 2011 [&lt;ulink linkID="999919" linkType="Reference"&gt;999919&lt;/ulink&gt;]. The first patient was dosed in 4Q09 [&lt;ulink linkID="1074105" linkType="Reference"&gt;1074105&lt;/ulink&gt;]. In December 2010, data were presented at the 52nd ASH meeting in Orlando, FL. In the 110 mg navitoclax plus BR cohort, three complete responses and three partial responses were observed. One complete response was observed in the 200 mg navitoclax plus BR cohort. In patients who received 110 mg navitoclax plus BR, six patients had &amp;gt; 50% reduction in circulating lymphocytes; at that time, two patients had been enrolled in the navitoclax plus FCR arm and  &amp;gt; 50% reduction in circulating lymphocytes was observed in both patients  [&lt;ulink linkID="1151758" linkType="Reference"&gt;1151758&lt;/ulink&gt;]. In December 2011, further data were presented at the 53rd ASH meeting in San Diego, CA. No clinically significant pharmacokinetic interaction between navitoclax and bendamustine was observed. Of 31 patients in both the arms, tumor response was observed in 4 of 5 patients in  navitoclax plus FCR arm and 18 of 26 patients in BR arm. In navitoclax + FCR arm, partial response (PR) and stable disease (SD) were observed in two patients each. In navitoclax + BR arms, 7 and 6 patients had PR and complete response, respectively.The combination of navitoclax plus BR was well tolerated. The MTD and recommended phase II dose of navitoclax in combination with bendamustine (70 mg/m2) and rituximab (375 mg/m2) was 250 mg. At that time, patient enrollment was ongoing in navitoclax + FCR arm [&lt;ulink linkID="1246558" linkType="Reference"&gt;1246558&lt;/ulink&gt;]. In June 2012, similar clinical data were presented at the 17th EHA Annual Congress in Amsterdam, the Netherlands. In the study, 27 CLL patients had  received navitoclax   in combination with standard FCR chemotherapy or standard BR chemotherapy.  Results showed antitumor activity in   93% of patients (n = 25), with 7 CR, 11 PR and 7 SD.    It was concluded that a Bcl-2 selective molecule (ABT-199), would lack thrombocytopenia toxicity and allow   higher drug exposures [&lt;ulink linkID="1302572" linkType="Reference"&gt;1302572&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Small-cell lung cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In March 2007, a non-randomized, open-label, uncontrolled,  phase I/IIa trial (&lt;ulink linkID="31827" linkType="Protocol"&gt;NCT00445198&lt;/ulink&gt;; M06-822) was initiated in subjects (expected n = 90)  with SCLC in the US and the UK. Endpoints included finding the MTD, DLT and initial efficacy assessment [&lt;ulink linkID="794585" linkType="Reference"&gt;794585&lt;/ulink&gt;]. In December 2007, data from this trial were presented at the 49th ASH Meeting in Atlanta, GA. In the phase I arm of the study, patients with refractory lymphoid malignancies (n = 27) received  10, 20, 40, 80, 160, 225 and 315 mg po qd for 14 days of a 21-day cycle; recruitment at the 315-mg dose was ongoing at that time. The drug showed linear pharmacokinetics, with average t1/2 of 14 to 20 h. The most serious adverse events noted were grade 3 cough exacerbation and pneumonia in two patients taking doses of 160 and 10 mg respectively, and four cases of grade 3 thrombocytopenia in patients taking doses of 80 mg and above. Three patients showed significant reductions in tumor burden [&lt;ulink linkID="858420" linkType="Reference"&gt;858420&lt;/ulink&gt;], [&lt;ulink linkID="859040" linkType="Reference"&gt;859040&lt;/ulink&gt;]. In June 2008, data were presented at the 44th annual ASCO meeting in Chicago, IL. At that time, the dose currently being tested was 440 mg. Strong signs of antitumor activity had been observed, dose escalation was ongoing [&lt;ulink linkID="912334" linkType="Reference"&gt;912334&lt;/ulink&gt;]. In October 2008, similar data were presented at the 20th EORTC-NCI-AACR symposium in Geneva, Switzerland.  Dose-finding in this study was ongoing at that time [&lt;ulink linkID="950321" linkType="Reference"&gt;950321&lt;/ulink&gt;]. In December 2008,  data were presented at the 50th ASH meeting in San Francisco, CA, establishing the maximum tolerated dose as 315 mg [&lt;ulink linkID="967207" linkType="Reference"&gt;967207&lt;/ulink&gt;]. By June 2009, the phase IIa portion of this trial was underway  [&lt;ulink linkID="1028756" linkType="Reference"&gt;1028756&lt;/ulink&gt;], and enrollment was completed in 4Q 2009 [&lt;ulink linkID="1094115" linkType="Reference"&gt;1094115&lt;/ulink&gt;]. In June 2010, data from the phase IIa portion were presented at the 46th ASCO meeting in Chicago, IL. Patients (n = 39) received navitoclax at 325 mg qd, in a 21-day cycle, following a 7-day lead-in titration dose of 150 mg. A partial response was seen in one patient;  stable and progressive disease were seen in 9 and 27 patients, respectively. Median PFS and time-to-progression were both 50 days.  Overall, navitoclax had an acceptable safety profile [&lt;ulink linkID="1104623" linkType="Reference"&gt;1104623&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In April 2009, a non-randomized, open-label, dose-escalating, phase Ib trial (&lt;ulink linkID="51373" linkType="Protocol"&gt;NCT00878449&lt;/ulink&gt;, M10-234) was planned in subjects (expected n = 35) with SCLC. The patients were to receive 150 mg of navitoclax daily for 5 days in combination with etoposide/&lt;ulink linkID="51933" linkType="Drug"&gt;cisplatin&lt;/ulink&gt;. Primary endpoints would be safety, pharmacokinetics, determination of MTD and recommended phase II dose. The trial was expected to complete in March 2011 [&lt;ulink linkID="999921" linkType="Reference"&gt;999921&lt;/ulink&gt;]. The first patient was dosed in 4Q 09 [&lt;ulink linkID="1074105" linkType="Reference"&gt;1074105&lt;/ulink&gt;]. By June 2010, the study was still ongoing [&lt;ulink linkID="1104623" linkType="Reference"&gt;1104623&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prostate cancer&lt;/subtitle&gt;In April 2013, a randomized, open-label, parallel-group, safety/efficacy phase II trial (&lt;ulink linkID="120648" linkType="Protocol"&gt;NCT01828476&lt;/ulink&gt;; 081214) was expected to be initiated in the US by the &lt;ulink linkID="20638" linkType="Company"&gt;University of Medicine and Dentistry, New Jersey,&lt;/ulink&gt; in patients (n = 53) with metastatic castrate refractory prostate cancer. The trial was to evaluate ABT-263/abiraterone or ABT-263/&lt;ulink linkID="10309" linkType="Drug"&gt;abiraterone&lt;/ulink&gt; and hydroxychloroquine and was expected to complete in April 2016; in november 2013, the investigator-led trial was initiated [&lt;ulink linkID="1413466" linkType="Reference"&gt;1413466&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Solid tumors&lt;/subtitle&gt;In 4Q 2009, a phase I trial (M11-958) began in patients (expected n = 60) with solid tumors. Subjects would receive either navitoclax, navitoclax plus &lt;ulink linkID="11961" linkType="Drug"&gt;erlotinib&lt;/ulink&gt;, or navitoclax plus &lt;ulink linkID="2871" linkType="Drug"&gt;irinotecan&lt;/ulink&gt; [&lt;ulink linkID="1074105" linkType="Reference"&gt;1074105&lt;/ulink&gt;]. In November 2011, preliminary data  from a phase I, open-label study were presented  at the 23rd AACR-NCI-EORTC International Conference in San Francisco, CA.    In 3-week, 21-day treatment cycles, patients (n = 14) received navitoclax (150 mg qd po) and irinotecan (180, 250 or 350 mg/m2 q3w, iv) , and in weekly 21-day treatment cycles, patients (n = 17) received navitoclax and irinotecan (75 or 100 mg/m2). Of the 31 patients, all were evaluable for safety, 22 for navitoclax pharmacokinetics and 17 were evaluable for irinotecan pharmacokinetics. Both did not affect each other's  pharmacokinetics. The respective Cmax, Tmax and AUC24 values of navitoclax were 0.013 microg/ml/mg, 8.3 h and 0.157 microg.h/ml/mg when given alone and 0.009 microg/ml/mg, 14.1 h and 0.129 microg.h/ml/mg when given in combination with irinotecan. The 150 mg navitoclax and 75 mg/m2 irinotecan was the recommended phase dose in the weekly regimen. Of the 17 patients, 2 showed partial response, 6 had stable disease and 9 had progressive disease [&lt;ulink linkID="1239255" linkType="Reference"&gt;1239255&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In 3Q09, a phase Ib trial (M10-589) began in patients (expected n = 25) with solid tumors. Subjects would receive  navitoclax plus &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; or &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; [&lt;ulink linkID="1074105" linkType="Reference"&gt;1074105&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2009, a non-randomized, open-label, pharmacokinetic, phase Ib trial (&lt;ulink linkID="52978" linkType="Protocol"&gt;NCT00887757&lt;/ulink&gt;; M10-588) began in patients (expected n = 25) in the US with solid tumors. The study would evaluate the safety of navitoclax in combination with &lt;ulink linkID="3199" linkType="Drug"&gt;gemcitabine&lt;/ulink&gt;.  The trial was estimated to complete in August 2011 [&lt;ulink linkID="1049733" linkType="Reference"&gt;1049733&lt;/ulink&gt;], [&lt;ulink linkID="1049766" linkType="Reference"&gt;1049766&lt;/ulink&gt;]. In June 2011, data were presented at the 47th ASCO meeting in Chicago, IL. Preliminary pharmacokinetics showed no interaction between the two drugs. The most common grade 3 or 4 adverse event was thrombocytopenia (n = 15) and three patients discontinued due to a DLT. Antitumor activity was seen in seven patients who achieved stable disease while 24 subjects showed progressive disease. At that time, enrollment in the 28-day dose-escalation period of the trial was ongoing. The study would also be expanded to include pancreatic cancer patients [&lt;ulink linkID="1195378" linkType="Reference"&gt;1195378&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2009, a non-randomized, open-label, pharmacokinetic, phase Ib trial (&lt;ulink linkID="52972" linkType="Protocol"&gt;NCT00888108&lt;/ulink&gt;; M10-338) began in patients (expected n = 25) in the UK and Netherlands with solid tumors. The study would evaluate the safety of navitoclax in combination with &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt;.The trial was estimated to complete in June 2011 [&lt;ulink linkID="1049754" linkType="Reference"&gt;1049754&lt;/ulink&gt;], [&lt;ulink linkID="1049733" linkType="Reference"&gt;1049733&lt;/ulink&gt;]. In June 2011, data were presented at the 47th ASCO meeting in Chicago, IL.     Of the 21 patients evaluable for efficacy, 1 showed a confirmed partial response, 9 had stable disease and 7 had progressive disease. Navitoclax 150 mg (days 1 to 5) plus 75 mg/m2 docetaxel was the MTD. At that time, the 28-day dose escalation portion of the study was enrolling patients [&lt;ulink linkID="1195103" linkType="Reference"&gt;1195103&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2008,  data  from  phase I studies  were presented at the 20th EORTC-NCI-AACR symposium in Geneva, Switzerland. Safety and pharmacokinetics of navitoclax were investigated for 14 days of a 21-day cycle in patients with relapsed or refractory lymphoma, SCLC/solid tumors and CLL in trials M06-822 (n = 33, patients receiving 10 to 475 mg navitoclax) and M06-873 (n = 14, patients receiving 10 to 250 mg navitoclax). The objective was to determine maximum tolerated dose of navitoclax. Dose-limiting toxicities such as thrombocytopenia and respiratory failure had been reported by that time and dose-finding in these studies was ongoing  [&lt;ulink linkID="950321" linkType="Reference"&gt;950321&lt;/ulink&gt;]. In December 2008, further data presented at the 50th ASH meeting in San Francisco, CA, showed that navitoclax demonstrated oral bioavailability with a half-life of 14 to 20 h, and one patient showed a 99% reduction in CLL tumor size with four cycles of navitoclax at 40 mg [&lt;ulink linkID="969013" linkType="Reference"&gt;969013&lt;/ulink&gt;], [&lt;ulink linkID="969112" linkType="Reference"&gt;969112&lt;/ulink&gt;], [&lt;ulink linkID="967856" linkType="Reference"&gt;967856&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2008, a randomized, open-label single-dose phase I trial (&lt;ulink linkID="47966" linkType="Protocol"&gt;NCT00743028&lt;/ulink&gt;, M10-454), was initiated in patients (expected n = 36) with cancer in the US. Primary endpoints were  an assessment of bioavailability of either a single oral 200 mg dose of  a capsule formulation of navitoclax compared to  the current 25 mg/ml  liquid formulation, a single oral 200 mg of a 50 mg/ml liquid formulation of navitoclax compared to that of the current 25 mg/ml, or a single oral 400 mg dose of a capsule formulation of navitoclax compared to a single 200 mg dose of the current 25 mg/ml liquid formulation. Further primary endpoints were an evaluation of the pharmacokinetic profile of an oral dosing of the capsule formulation of navitoclax at either 400 mg administered once daily, or 200 mg administered twice daily. In January 2009, recruitment was still ongoing and the trial was expected to be completed in October 2009 [&lt;ulink linkID="985618" linkType="Reference"&gt;985618&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Diffuse large B-cell lymphoma&lt;/subtitle&gt;In August 2016, clinical data from phase I study were presented at the 24th EFMC-ISMC Symposium in Manchester, UK. Navitoclax showed single agent activity in CLL and lymphoma and concentration dependent thrombocytopenia [&lt;ulink linkID="1791731" linkType="Reference"&gt;1791731&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;An open-label, randomized, phase II trial (&lt;ulink linkID="80362" linkType="Protocol"&gt;NCT01423539&lt;/ulink&gt;; GP27814) was planned in August 2011 in patients with relapsed DLBCL. Patients were to receive navitoclax in combination with &lt;ulink linkID="47000" linkType="Drug"&gt;bendamustine&lt;/ulink&gt; and &lt;ulink linkID="6736" linkType="Drug"&gt;rituximab&lt;/ulink&gt;.  However the trial was withdrawn in June 2012 prior to enrollment [&lt;ulink linkID="1323937" linkType="Reference"&gt;1323937&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other clinical data&lt;/subtitle&gt;In April 2011, data were presented at the 102nd AACR meeting in Orlando, FL. A new oral lipid formulation of navitoclax was prepared for phase II/III trials, with improved shelf life compared with the previous formulation. Two randomized crossover studies were conducted to compare the bioavailability of the two formulations. The formulations were found to be bioequivalent [&lt;ulink linkID="1175476" linkType="Reference"&gt;1175476&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2010, clinical data were presented at the 32nd NMCS meeting in Minneapolis, MN. In phase I and II clinical trials (treated n = 43; evaluable n = 35), a total of six patients had confirmed partial responses, five had unconfirmed partial responses, ten had stable disease and eight had a greater than 50% reduction in lymphocyte count at a 2-month follow up. The overall response rate to navitoclax was 31% [&lt;ulink linkID="1106398" linkType="Reference"&gt;1106398&lt;/ulink&gt;], [&lt;ulink linkID="1100901" linkType="Reference"&gt;1100901&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2009, data from three phase I studies (MD6-814, MD6-822 and MD6-873) analyzed using a simulation model to evaluate the exposure/response relationship in navitoclax-induced thrombocytopenia and to determine the DLT and recommended dose for a phase III study in chronic lymphoid leukemia patients were presented at the AACR-NCI-EORTC International Conference in Boston, MA. The analysis included data from 103 patients from the three studies and found continuous dosing of navitoclax to minimize platelet variability across cycles and was therefore superior compared with 14/21-day dosing schedules. The incidence of Grade 4 thrombocytopenia was shown to be similar between trials but the continuous dosing schedule had a trend toward a lower rate of Grade 3 thrombocytopenia [&lt;ulink linkID="1059896" linkType="Reference"&gt;1059896&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;&lt;subtitle&gt;Navitoclax&lt;/subtitle&gt;In December 2016, preclinical data were presented at the 39th Annual San Antonio Breast Cancer Symposium in San Antonio, TX. In HER2+ patient pleural effusions of patient-derived xenograft (PDX) model, PDX8 and 12, in NOD/SCID mice, enhanced cytotoxic effect of T-DM1 treatment (10 mg/kg intraperitoneal) was observed after ABT-263 induced BCL-2/XL inhibition. Minimized adverse events associated with T-DM1 and ABT-263 was observed after tumor targeting treatment with T-DM1 + ABT-263 [&lt;ulink linkID="1885263" linkType="Reference"&gt;1885263&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2016, preclinical data were presented at the 24th EFMC-ISMC Symposium in Manchester, UK. Against BCL-2, BCL-X (L), BCL-W and MCL-1, navitoclax exhibited Ki values of  0.04, 0.05, 7 and &amp;gt; 440 nM, respectively. In RS4;11 (BCL2) and H146 (BCL-XL) cell lines, navitoclax had EC50 values of 110 and 75 nM, respectively [&lt;ulink linkID="1791731" linkType="Reference"&gt;1791731&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  April 2016, preclinical data were presented at the 107th AACR Annual Meeting in New Orleans, LA, USA. In H1963 and H146 cells, combination of &lt;ulink linkID="95929" linkType="Drug"&gt;ABBV-075&lt;/ulink&gt; and &lt;ulink linkID="70895" linkType="Drug"&gt;venetoclax&lt;/ulink&gt; or navitoclax appeared to have synergistic effect, which had a positive correlation with BCL2 expression [&lt;ulink linkID="1749345" linkType="Reference"&gt;1749345&lt;/ulink&gt;]. Further preclinical data were presented at the same conference. In two patient-derived xenograft (PDX) models of advanced HER2+ER- resistant disease (PDX8, PDX12), pulsed administration of ABT-263 was associated with weight loss to vehicle levels and offered platelets recovery. Pathological responses of &lt;ulink linkID="36669" linkType="Drug"&gt;T-DM1&lt;/ulink&gt; + ABT-263 combination mimicked to those observed with T-DM1 + ABT-737 combination [&lt;ulink linkID="1754083" linkType="Reference"&gt;1754083&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2013, preclinical data were presented at 2013 Annual European Congress of Rheumatology in Madrid, Spain. In murine models of lupus nephritis (lupus-prone (NZB × NZW)F1 mice), navitoclax (3, 10 or 30 mg/kg) significantly reduced the incidence of severe proteinuria (&amp;gt;/= 300 mg/dl) and mortality in a dose-dependent manner compared with vehicle. In ex vivo human cell cultures, navitoclax showed a rapid reduction of both stimulated and unstimulated human lymphocyte counts; B cells showed higher sensitivity to navitoclax than T-cells [&lt;ulink linkID="1441913" linkType="Reference"&gt;1441913&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2013, preclinical data were publihsed.  Data demonstrated that a combination of  ABT-263 and &lt;ulink linkID="68676" linkType="Drug"&gt;G-963&lt;/ulink&gt; was synergistic in the majority of NSCLC and pancreatic cancer cell lines. The combination was more effective than either single-agent in the KRAS mutant H2122 xenograft model. Addition of &lt;ulink linkID="49560" linkType="Drug"&gt;GDC-0941&lt;/ulink&gt; to the treatment combination increased cell killing compared to double or single-agent treatment [&lt;ulink linkID="1403232" linkType="Reference"&gt;1403232&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2011, preclinical data were presented at the 23rd AACR-NCI-EORTC International Conference in San Francisco, CA. In vitro in A375 and A2058 cells, combination treatment with vemurafenib and navitoclax was found to reduce the cell viability greatly when compared with vemurafenib and navitoclax alone. In nude heige mice implanted with melanoma cells A375 and A2058, the vemurafenib (100 mg/kg) and navitoclax combination reduced the tumor volume greatly and delayed the time to progression when compared with vemurafenib and navitoclax monotherapies and vehicle [&lt;ulink linkID="1239184" linkType="Reference"&gt;1239184&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2011, preclinical data were published which demonstrated the drug may have a use in treating breast cancer with high Bcl-2 levels [&lt;ulink linkID="1208492" linkType="Reference"&gt;1208492&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2011,  data were presented at the 102nd AACR meeting in Orlando, FL.   Navitoclax showed synergistic effects against a panel of cancer cell lines in combination with chemotherapeutic (gemcitabine or paclitaxel) and targeted agents (that inhibit EGFR, PI3K and MAP kinase). Antitumor activity was observed with the combination of navitoclax and MEK inhibitor in NSCLC cells. In ovarian cancer cell lines and tissues, a correlation was observed between high Bcl-xL expression and synergistic activity of the paclitaxel/navitoclax combination. Synergistic effects were more frequently observed with the combination of navitoclax and MEK inhibitor in cell lines harboring activating mutations in the EGFR/Ras/Raf pathway. In mice bearing KRAS tumors, greater reduction in tumor volume was observed with the combination of navitoclax (100 mg/kg qd) and MEK inhibitor (12.5 mg/kg qd) when compared with either drug alone [&lt;ulink linkID="1177394" linkType="Reference"&gt;1177394&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2011, preclinical data were presented at the 241st ACS meeting in Anaheim, CA. In cell samples obtained from  CLL patients, the agent induced rapid apoptosis [&lt;ulink linkID="1174495" linkType="Reference"&gt;1174495&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2010, preclinical data were presented at the 22nd EORTC-NCI-AACR Symposium in Berlin, Germany. In vitro, the IC50 value of navitoclax in KIT-negative cells was 100 nM and in KIT-positive cells was in the range of 2 to 10 microM. A combination of navitoclax and &lt;ulink linkID="11460" linkType="Drug"&gt;imatinib&lt;/ulink&gt; demonstrated a dose-dependent increase of apoptosis, and an increased induction of caspase 3 and 7 [&lt;ulink linkID="1143998" linkType="Reference"&gt;1143998&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2008, preclinical data were reported at the 235th ACS National Meeting in New Orleans, LA, which showed navitoclax enhanced chemotherapy efficacy and was orally active in in vivo xenograft models of SCLC [&lt;ulink linkID="889579" linkType="Reference"&gt;889579&lt;/ulink&gt;], [&lt;ulink linkID="890298" linkType="Reference"&gt;890298&lt;/ulink&gt;]. In October 2008, similar data were presented at the 20th EORTC-NCI-AACR meeting in Geneva, Switzerland [&lt;ulink linkID="950529" linkType="Reference"&gt;950529&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; In October 2007, preclinical data were presented at the Fourth GTCBio Tumor Progression &amp;amp; Therapeutic Resistance Conference in Philadelphia, PA. In combination with the EGFR inhibitor &lt;ulink linkID="11961" linkType="Drug"&gt;erlotinib&lt;/ulink&gt;, navitoclax showed synergistic growth inhibition in cell lines with either de novo or acquired resistance to navitoclax as a single agent [&lt;ulink linkID="838679" linkType="Reference"&gt;838679&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2007, preclinical data on navitoclax were presented at the 98th AACR meeting in Los Angeles, CA. Navitoclax was examined in a panel of human SCLC tumor lines and a wide range of sensitivities were observed both in vitro and in vivo. Sensitivity to navitoclax correlated well with expression of the Bcl-2 family members targeted by this compound. The drug (100 mg/kg/qd, po  x 21) was highly efficacious in four xenograft models of SCLC with a significant number of durable complete tumor regressions observed in each case. Significant antitumor activity was observed in four additional SCLC models. The efficacy of navitoclax was comparable or superior to the activity of numerous cytotoxic agents. Navitoclax was able to regress H146 tumors more effectively than a maximally tolerated dose of docetaxel. A single 100-mg/kg dose of navitoclax induced an approximately 10-fold increase in activated caspase-3 relative to vehicle-treated controls [&lt;ulink linkID="778262" linkType="Reference"&gt;778262&lt;/ulink&gt;]. After a single iv or po dose in dogs, circulating platelet counts decreased rapidly and concentration-dependently with a nadir at approximately 6 h post administration. Platelet counts returned to near normal levels within several days post dose, accompanied by an increase in both mean platelet volume and percent of reticulated platelets. During this rebound period, analysis of platelets by aggregometry indicated that returning platelets were fully functional. During chronic administration, platelet counts also decreased rapidly after initial dosing, but exhibited evidence of dose-dependent rebound during the dosing period. Whole body scintography utilizing Indium labeled platelets in dogs indicated that the liver primarily mediates platelet clearance after compound administration. These data suggest that navitoclax preferentially affects circulating platelets rather than abrogating platelet production in the bone marrow. A less active enantiomer control had no effect on circulating platelets in animals suggesting an underlying mechanism that is dependent on inhibition of anti-apoptotic Bcl-2 family proteins. The unusually rapid kinetics of platelet clearance and recovery suggests that the drug-induced thrombocytopenia elicited by these Bcl-2 family protein inhibitors is distinct from that observed with conventional cytotoxic chemotherapy [&lt;ulink linkID="780804" linkType="Reference"&gt;780804&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2006, preclinical data on navitoclax were presented at the 48th ASH meeting in Orlando, FL. The efficacy study evaluated the activity of navitoclax in several non-Hodgkin's lymphoma xenograft models. navitoclax had a Ki value of 1 nm against Bcl-2, Bcl-XL, and Bcl-w. In vivo, navitoclax was administered at 100 mg/kg/day for 21 days, and evaluated as monotherapy and in combination with etoposide, vincristine, modified CHOP, R-CHOP, &lt;ulink linkID="15954" linkType="Drug"&gt;bortezomib&lt;/ulink&gt;, rapamycin, and &lt;ulink linkID="6736" linkType="Drug"&gt;rituximab&lt;/ulink&gt;. In a B-cell lymphoma model, navitoclax alone significantly inhibited tumor growth by 50%. In combination with vincristine and rituximab a significant increase in inhibition was seen compared to monotherapy. navitoclax + vincristine and navitoclax + rituximab both resulted in approximately 70% complete tumor cell regression. Navitoclax monotherapy in mantle cell lymphoma resulted in a 40% inhibition of tumor growth, which increased when combined with bortezomib and R-CHOP (90%). In combination with &lt;ulink linkID="15954" linkType="Drug"&gt;bortezomib&lt;/ulink&gt; in a multiple myeloma model, 75% tumor cell regression was observed at the maximum-tolerated dose [&lt;ulink linkID="747353" linkType="Reference"&gt;747353&lt;/ulink&gt;], [&lt;ulink linkID="749346" linkType="Reference"&gt;749346&lt;/ulink&gt;]. The compound had robust antitumor activity in xenograft models of small-cell lung carcinoma and B-cell lymphomas. In mice, navitoclax3 caused an acute drop in circulating platelets, with the nadir occurring around 6 h after treatment [&lt;ulink linkID="747308" linkType="Reference"&gt;747308&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Further preclinical data were also presented  in December 2006, at the 48th ASH meeting in Orlando, FL.   In the study,  navitoclax induced a dose-dependent thrombocytopenia in dogs, which was fully reversible after compound cessation [&lt;ulink linkID="747683" linkType="Reference"&gt;747683&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2006, preclinical data on navitoclax were presented at the 18th EORTC-NCI-AACR meeting in Prague, Czech Republic. Navitoclax had potent affinity for Bcl-X, Bcl-2 and Bcl-W, with a spectrum of activity similar to ABT-737. The drug demonstrated single agent activity against a subset of tumor cell lines (small-cell lung cancer (SCLC), lymphoma, leukemia), and was active when administered orally to mice with SCLC xenografts [&lt;ulink linkID="739334" linkType="Reference"&gt;739334&lt;/ulink&gt;]. Similar data were presented in April 2008, at the 235th  ACS National Meeting in New Orleans, LA [&lt;ulink linkID="890298" linkType="Reference"&gt;890298&lt;/ulink&gt;], [&lt;ulink linkID="897399" linkType="Reference"&gt;897399&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other series&lt;/subtitle&gt;In April 2017, in vitro data were presented at the 108th AACR Annual Meeting in Washington DC. In harvested ascites cells from high-grade serous ovarian cancer patient-derived xenografts (PDX) mice model, the combination treatment (96 h) of &lt;ulink linkID="56544" linkType="Drug"&gt;GDC-0973&lt;/ulink&gt; (1 microM) + ABT-263 (1 microM) reduced cell number in vitro. In in vivo PDX models, the GDC-0973 + ABT-263 combination treatment effectively reduced the tumor burden [&lt;ulink linkID="1914091" linkType="Reference"&gt;1914091&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2013, preclinical data were  presented at the  the 104th AACR Meeting in Washington. Apigenin enhanced ABT-263-induced antitumor efficacy in SCID mice bearing xenografts of HCT116 cells, treated with ABT-263 (100 mg/kg), apigenin (25 mg/kg) or their combination. Apigenin enhanced ABT-263-induced apoptosis in HCT116, DLD1, SW48 and HT29 colon cancer cell lines. In HCT116 and DLD1 colon cancer cell lines, apigenin downregulated Mcl-1-enhanced ABT-263-triggered cell death. Apigenin inactivation of ERK led to ABT-263-induced cell death. Inactivation of AKT and/or ERk by apigenin and ABT-263, resulted in upregulation of Bim and activation of Bax kinases [&lt;ulink linkID="1401570" linkType="Reference"&gt;1401570&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2010, a new series with the benzoylsulfonamide portion of navitoclax replaced by a quinazolinesulfonamide scaffold had been synthesized. One of the best compounds exhibited IC50 values of 7 nM, 9nM and 440 nM for Bcl-xL, Bcl-2 and Bcl-w respectively, was specific over Mcl-1 and was active against small-cell lung carcinoma cell lines H146, H889 and H1963 with EC50 values of 0.61 microM, 0.21 microM and 0.17 microM  respectively [&lt;ulink linkID="1179334" linkType="Reference"&gt;1179334&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2004, preclinical data on A-371191 were presented at the 95th AACR meeting in Orlando, FL. A-371191 binding affinity was greater for Bcl-xL as compared to other Bcl-2 family members using a fluorescent polarization assay. The Ki values  were 0.5, 40, 180 and 1300 microM for Bcl-xL, Bcl-2, Bcl-w and Bcl-b, respectively. A-371191 co-localized with the mitochondrial specific dye MitoTracker in NIH-H460 cells using a BODIPY Texas Red-X, succinimidyl ester labeled A-371191 derivative, suggesting that A-371191 not only accumulated in cells, but was also targeted to the mitochondria. To test A-371191 activity in vitro a matched pair of neomycin-transfected (HL60/neo) and Bcl-xL-transfected HL-60 human acute myeloid leukemia cells were used. It was found by Western blot analysis that HL-60/Bcl-xL cells overexpressed Bcl-xL as compared to HL-60/neo cells, both expressed a moderate level of Bcl-2, Bax and Bak and undetectable levels of Bcl-w. HL-60/Bcl-xL cells were less sensitive to a variety of chemocytotoxic agents including paclitaxel, doxorubicin, methotrexate, Gemzar, cisplatin and etoposide, as compared to HL-60/neo cells. In vitro, HL-60/Bcl-xL cell sensitivity to cisplatin and doxorubicin was restored similar to the HL-60/neo cells when co-treated with 3.2 and 1.8 microM A-371191, respectively [&lt;ulink linkID="531010" linkType="reference"&gt;531010&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2003, preclinical data on this program, including compounds A-438744 and A-385358, were presented at the 45th ASH meeting in San Diego, CA. The compounds induced a decrease in mitochondrial membrane potential, caspase activation and PS/annexin. Caspase 9 -/- mouse epithelial fibroblasts were resistant to A-438744, but Jurkat I9.2 caspase 8 mutants were readily killed. HL-60 cells treated with a caspase 9 inhibitor were protected from the killing action of A-438744. Cell killing was primarily via the mitochondrial pathway of apoptosis. Translocation of apoptosis inducing factor from the mitochondrial inner membrane to the nucleus in A-438744-treated cells suggested a second, caspase-independent mechanism of action. Studies in primary leukemia samples and in combination with chemotherapeutic agents were to be carried out. Neither A-438744 nor A-385358 were soluble in serum, and will not enter the clinic [&lt;ulink linkID="516292" linkType="reference"&gt;516292&lt;/ulink&gt;], [&lt;ulink linkID="516052" linkType="reference"&gt;516052&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2003, preclinical data on this program were presented at the BIO 2003 meeting in Washington, DC. In vitro studies showed that A-317267 possessed a nanomolar affinity for Bcl-xL, and in A549 cells (a non-small-cell lung carcinoma cell line), the compound induced cytochrome C release, caspase activation and changes in cellular morphology typically associated with cellular apoptosis. However, studies in FL5.12 cells failed to prove this effect was due to an interaction between Bcl-xL and A-317267. A-385358 was subsequently synthesized from A-317267 and further studies showed the new lead compound to possess definite anti Bcl-xL and Bcl-2 activity. Studies in a range of cell lines demonstrated that A-385358 possessed EC50 values in a range of 1.2 to over 20 microM. A-549 tumor xenograft studies of A-385358 in combination with paclitaxel then showed A-385358 to exhibit significant tumor-reducing capabilities, but only in combination and not on its own. Preclinical studies on this compound were ongoing at this time [&lt;ulink linkID="494551" linkType="reference"&gt;494551&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In June 2018, the EMA's Pediatric Committee adopted a positive opinion on a product-specific waiver recommending the obligation to submit data from trials in children be waived for the treatment of myelofibrosis [&lt;ulink linkID="2055591" linkType="Reference"&gt;2055591&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2009, the EMEA's Pediatric Committee (PDCO) adopted a positive opinion on a pediatric investigation plan for the drug for oncology [&lt;ulink linkID="1060120" linkType="Reference"&gt;1060120&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2007, Genentech agreed to codevelop Abbott's navitoclax. The companies  would both be responsible for all further development and commercialization [&lt;ulink linkID="808616" linkType="Reference"&gt;808616&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 1999, Abbott and Idun entered into a worldwide R&amp;amp;D agreement to focus on the discovery and development of products to treat cancer, via modulation of select proteins including Bcl-2, which ultimately regulate apoptosis [&lt;ulink linkID="311280" linkType="reference"&gt;311280&lt;/ulink&gt;]. The agreement was extended in April 2001 [&lt;ulink linkID="406182" linkType="reference"&gt;406182&lt;/ulink&gt;] and concluded in December 2003 [&lt;ulink linkID="596648" linkType="Reference"&gt;596648&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 1998, Idun was issued with &lt;ulink linkID="IN2398281" linkType="Patent"&gt;US-05691179&lt;/ulink&gt;, &lt;ulink linkID="IN2396889" linkType="Patent"&gt;US-05700638&lt;/ulink&gt; and &lt;ulink linkID="IN2453700" linkType="Patent"&gt;US-05702897&lt;/ulink&gt;, covering the apoptotic Bax gene. The patents cover methods of screening for agents that modulate apoptosis [&lt;ulink linkID="283938" linkType="reference"&gt;283938&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2013-03-15T00:00:00.000Z</StatusDate><Source id="1498723" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="2404">Lupus nephritis</Indication><StatusDate>2013-03-15T00:00:00.000Z</StatusDate><Source id="1498723" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2012-02-01T00:00:00.000Z</StatusDate><Source id="1259334" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2012-02-01T00:00:00.000Z</StatusDate><Source id="1259334" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2013-03-15T00:00:00.000Z</StatusDate><Source id="1498723" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2012-06-28T00:00:00.000Z</StatusDate><Source id="1323937" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="203">Lymphoma</Indication><StatusDate>2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="203">Lymphoma</Indication><StatusDate>2013-03-15T00:00:00.000Z</StatusDate><Source id="1498723" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2013-03-15T00:00:00.000Z</StatusDate><Source id="1498723" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2012-02-01T00:00:00.000Z</StatusDate><Source id="1259334" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2012-02-01T00:00:00.000Z</StatusDate><Source id="1259334" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2012-02-01T00:00:00.000Z</StatusDate><Source id="1259334" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24182">Idun Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>2003-12-31T00:00:00.000Z</StatusDate><Source id="596648" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2012-02-01T00:00:00.000Z</StatusDate><Source id="1259334" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2013-03-15T00:00:00.000Z</StatusDate><Source id="1498723" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2013-03-15T00:00:00.000Z</StatusDate><Source id="1498723" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="203">Lymphoma</Indication><StatusDate>2012-02-01T00:00:00.000Z</StatusDate><Source id="1259334" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2013-03-15T00:00:00.000Z</StatusDate><Source id="1498723" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2009-07-31T00:00:00.000Z</StatusDate><Source id="1049754" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2009-07-31T00:00:00.000Z</StatusDate><Source id="1049754" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2009-08-31T00:00:00.000Z</StatusDate><Source id="1049766" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2007-06-30T00:00:00.000Z</StatusDate><Source id="985667" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2007-03-06T00:00:00.000Z</StatusDate><Source id="794585" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2011-10-21T00:00:00.000Z</StatusDate><Source id="1242860" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="203">Lymphoma</Indication><StatusDate>2007-06-26T00:00:00.000Z</StatusDate><Source id="808616" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2011-08-17T00:00:00.000Z</StatusDate><Source id="1323937" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2009-07-31T00:00:00.000Z</StatusDate><Source id="1049754" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2009-08-31T00:00:00.000Z</StatusDate><Source id="1049766" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2009-07-31T00:00:00.000Z</StatusDate><Source id="1049754" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="203">Lymphoma</Indication><StatusDate>2006-11-10T00:00:00.000Z</StatusDate><Source id="745104" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2011-10-21T00:00:00.000Z</StatusDate><Source id="1242860" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2007-03-06T00:00:00.000Z</StatusDate><Source id="794585" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2007-06-30T00:00:00.000Z</StatusDate><Source id="985667" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072507">AbbVie Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072507">AbbVie Inc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072507">AbbVie Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072507">AbbVie Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072507">AbbVie Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072507">AbbVie Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="203">Lymphoma</Indication><StatusDate>2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072507">AbbVie Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2013-01-02T00:00:00.000Z</StatusDate><Source id="1353481" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072507">AbbVie Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2404">Lupus nephritis</Indication><StatusDate>2013-03-15T00:00:00.000Z</StatusDate><Source id="1441913" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24182">Idun Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>1999-01-12T00:00:00.000Z</StatusDate><Source id="311280" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="203">Lymphoma</Indication><StatusDate>2009-01-31T00:00:00.000Z</StatusDate><Source id="985644" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="203">Lymphoma</Indication><StatusDate>2009-01-31T00:00:00.000Z</StatusDate><Source id="985644" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2007-06-26T00:00:00.000Z</StatusDate><Source id="808616" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>1999-01-12T00:00:00.000Z</StatusDate><Source id="311280" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2009-01-23T00:00:00.000Z</StatusDate><Source id="983719" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1072507">AbbVie Inc</OwnerCompany><Country id="US">US</Country><Indication id="1261">Small-cell lung cancer</Indication><AwardedIndication>Treatment of small cell lung cancer.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2007-12-19T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1072507">AbbVie Inc</OwnerCompany><Country id="US">US</Country><Indication id="1734">Chronic lymphocytic leukemia</Indication><AwardedIndication>Treatment of chronic lymphocytic leukemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2007-12-19T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-03718"><Name>Bcl-xL Bcl-2 associated death promotor</Name><SwissprotNumbers><Swissprot>O35147</Swissprot><Swissprot>Q61337</Swissprot><Swissprot>Q92934</Swissprot></SwissprotNumbers></Target><Target id="PTGT-04081"><Name>Bcl-2 protein</Name><SwissprotNumbers><Swissprot>O02718</Swissprot><Swissprot>P10415</Swissprot><Swissprot>P10417</Swissprot><Swissprot>P49950</Swissprot><Swissprot>Q00709</Swissprot><Swissprot>Q9JJV8</Swissprot></SwissprotNumbers></Target><Target id="PTGT-09919"><Name>Apoptosis regulator Bcl w</Name><SwissprotNumbers><Swissprot>P70345</Swissprot><Swissprot>Q92843</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1022651">Conatus Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="13601">Abbott Laboratories</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="19446">Roche Holding AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CN(C)CC[C@H](CSc1ccccc1)Nc2ccc(cc2[N+](=O)[O-])S(=O)(=O)Nc3c4ccc(cc4ncn3)N5CCN(CC5)Cc6ccccc6c7ccc(cc7)Cl</Smiles><Smiles>CC1(CCC(=C(C1)CN2CCN(CC2)c3ccc(cc3)C(=O)NS(=O)(=O)c4ccc(c(c4)S(=O)(=O)C(F)(F)F)N[C@H](CCN5CCOCC5)CSc6ccccc6)c7ccc(cc7)Cl)C.Cl.Cl</Smiles><Smiles>CC1(CCC(=C(C1)CN2CCN(CC2)c3ccc(cc3)C(=O)NS(=O)(=O)c4ccc(c(c4)S(=O)(=O)C(F)(F)F)N[C@H](CCN5CCOCC5)CSc6ccccc6)c7ccc(cc7)Cl)C</Smiles><Smiles>CC1(CCN(CC1)c2ccc(cc2)C(=O)NS(=O)(=O)c3ccc(c(c3)[N+](=O)[O-])N[C@H](CCN(C)C)CSc4ccccc4)C</Smiles><Smiles>Cc1nc2cc(ccc2s1)c3ccc(cc3)C(=O)NS(=O)(=O)c4ccc(c(c4)[N+](=O)[O-])NC[C@@]56CC[C@H]7C[C@@H](C5)C[C@H]7C6</Smiles></StructureSmiles><Deals><Deal id="109880" title="Abbott and Genentech to develop AB-263 and ABT-869  "/><Deal id="113179" title="Abbott and Idun to discover apoptosis modulators for cancer "/></Deals><PatentFamilies><PatentFamily id="1088422" number="WO-2009073835" title="Oral compositions of ABT-263 for treating cancer"/><PatentFamily id="1257447" number="WO-2008070663" title="Companion diagnostic assays for cancer therapy"/><PatentFamily id="1306730" number="WO-2009155386" title="A process for the preparation of the apoptosis promoter ABT-263"/><PatentFamily id="1381447" number="WO-2010068684" title="Methods and compositions for specific modulation of MCL-1"/><PatentFamily id="1527588" number="WO-2009064938" title="Method of treating arthritis"/><PatentFamily id="1557913" number="WO-2010127191" title="Solid oral formulation of ABT-263"/><PatentFamily id="1658691" number="WO-2011031441" title="Therapy with a chimeric molecule and a pro-apoptotic agent"/><PatentFamily id="1737839" number="WO-2008030836" title="Treatment of myeoproliferative diseases"/><PatentFamily id="1827290" number="WO-2010093742" title="Methods and compositions for identifying, classifying and monitoring subject having Bcl-2 family inhibitor-resistant tumors and cancers"/><PatentFamily id="1920424" number="WO-2008064116" title="Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection"/><PatentFamily id="2081757" number="WO-2011034934" title="ABT-263 Crystalline forms and solvates for use in treating Bcl-2 protein related diseases"/><PatentFamily id="2146712" number="WO-09505750" title="Cell death regulator."/><PatentFamily id="215444" number="WO-2008082643" title="Companion diagnostic assays for cancer therapy"/><PatentFamily id="2450995" number="CN-102836160" title="A pharmaceutical composition for treating cancer"/><PatentFamily id="2476044" number="WO-2010127193" title="Stabilized lipid formulation of apoptosis promoter"/><PatentFamily id="2476060" number="WO-2010143074" title="Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor"/><PatentFamily id="2476061" number="WO-2010144464" title="Solid dispersions containing an apoptosis-promoting agent"/><PatentFamily id="2476067" number="WO-2010147899" title="Stable nanoparticulate drug suspension"/><PatentFamily id="2476202" number="WO-2011068863" title="Combination therapy for treating cancer and diagnostic assays for use therein"/><PatentFamily id="2476229" number="WO-2011079127" title="Abt-263 capsule"/><PatentFamily id="2678201" number="WO-2014020043" title="Combinations for the treatment of cancer"/><PatentFamily id="2709331" number="WO-2014047779" title="Pharmaceutical composition containing evodiamine and evodiamine derivative and Bcl-2 inhibitor and use thereof"/><PatentFamily id="2709639" number="WO-2014047782" title="Pharmaceutical composition containing resveratrol and resveratrol derivative and Bcl-2 inhibitor and use thereof"/><PatentFamily id="2709719" number="WO-2014047783" title="Pharmaceutical composition containing triptolide and triptolide derivative and Bcl-2 inhibitor and use thereof"/><PatentFamily id="2758125" number="WO-2014100080" title="Combination"/><PatentFamily id="2807491" number="WO-2014160071" title="Methods and compositions for the treatment of glutamine-addicted cancers"/><PatentFamily id="2834411" number="WO-2014190163" title="Combination therapy for MDS"/><PatentFamily id="2858305" number="US-09567641" title="Combination therapy for the treatment of cancer using an anti-c-met antibody"/><PatentFamily id="2873180" number="WO-2015010094" title="Differential BH3 mitochondrial profiling"/><PatentFamily id="290304" number="WO-2012071374" title="Methods of treatment using selective Bcl-2 inhibitors"/><PatentFamily id="2935269" number="WO-2015070020" title="Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors"/><PatentFamily id="2952287" number="WO-2015085325" title="Combination therapy for treating cancer"/><PatentFamily id="2961745" number="WO-2015095834" title="Cancer treatments using ERK1/2 and BCL-2 family inhibitors"/><PatentFamily id="2980242" number="WO-2015116735" title="Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders"/><PatentFamily id="3051358" number="WO-2015157120" title="Combination therapy comprising nanoparticles of a taxane and albumin with ABT-263 in methods for treating cancer"/><PatentFamily id="3055991" number="WO-2015160975" title="Combination therapies"/><PatentFamily id="3065367" number="WO-2015171591" title="Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents"/><PatentFamily id="3131705" number="WO-2016025652" title="Combinations of an ERK inhibitor and a Bcl-2 pathway modulator and related methods"/><PatentFamily id="3254178" number="WO-2016118855" title="Compositions and methods for selectively depleting senescent cells comprising death receptors"/><PatentFamily id="3278152" number="WO-2016126552" title="Combination therapies for treating cancers"/><PatentFamily id="3330290" number="US-08748108" title="Biomarkers for identifying patient classes"/><PatentFamily id="3434314" number="WO-2016176288" title="High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells"/><PatentFamily id="3494412" number="WO-2018033128" title="Use of Bcl-xL inhibitor and oncolytic virus in preparation of antitumor drug"/><PatentFamily id="3508190" number="WO-2017007858" title="Methods and compositions relating to proteasome inhibitor resistance"/><PatentFamily id="3562823" number="WO-2017037579" title="MDM2 Inhibitors and combinations thereof"/><PatentFamily id="3562825" number="WO-2017037586" title="Combination therapy using PI3K inhbitor and MDM2 inhibitor"/><PatentFamily id="3605671" number="US-20170108488" title="Array and method of use"/><PatentFamily id="373736" number="WO-2010127192" title="Lipid formulation of apoptosis promoter"/><PatentFamily id="3750223" number="US-20170224678" title="Inhibitors of Bcl-2"/><PatentFamily id="3939403" number="WO-2018022973" title="Methods and compositions to treat cancer"/><PatentFamily id="4060229" number="WO-2018092064" title="Combinations of MDM2 inhibitors and Bcl-xL inhibitors"/><PatentFamily id="4109567" number="CN-108159022" title="An adriamycin and abt-263 dual medicine nanometer carrier and preparation method thereof"/><PatentFamily id="4156913" number="WO-2018146506" title="Therapeutic derivatives"/><PatentFamily id="4190970" number="WO-2018164580" title="Biomarkers for cellular senescence"/><PatentFamily id="4191226" number="WO-2018165575" title="Warhead-containing peptidomimetic macrocycles as modulators of BFL-1"/><PatentFamily id="4292970" number="WO-2018222473" title="Bax activators and uses thereof in cancer therapy"/><PatentFamily id="4293577" number="US-20180344865" title="Methods of increasing fertility in a female subject"/><PatentFamily id="4434359" number="WO-2019054966" title="Chemotherapeutic drug composition"/><PatentFamily id="598081" number="WO-2011061222" title="Therapeutic combination comprising a CDC7 inhibitor and an antineoplastic agent"/><PatentFamily id="707969" number="WO-2009049841" title="Combination therapy of a type II anti-CD20 antibody with an anti-Bcl-2 active agent"/><PatentFamily id="817138" number="WO-2010127190" title="Salt of ABT-263 and solid-state forms thereof"/><PatentFamily id="881661" number="WO-2007040650" title="Apoptosis promoters"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>31</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>14</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>9</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>10</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University Medical Center Groningen" id="1007827"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Palo Alto Investors" id="1011545"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nerviano Medical Sciences Srl" id="1013717"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Centro Nacional de Investigaciones Oncologicas" id="1017946"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The University of Arkansas System" id="1018113"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Yeditepe University" id="1018251"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Asahi Kasei Corp" id="1022453"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Conatus Pharmaceuticals Inc" id="1022651"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Aileron Therapeutics Inc" id="1031301"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eutropics Pharmaceuticals Inc" id="1037741"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Oxford Centre for Diabetes, Endocrinology and Metabolism" id="1040172"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Epizyme Inc" id="1048714"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Seattle Children's Hospital" id="1049938"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BioMed Valley Discoveries" id="1063567"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tensha Therapeutics Inc" id="1064821"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AbbVie Inc" id="1072507"/><CountAsOwner>17</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>17</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dinkum International Investment (Hong Kong) Co Ltd" id="1094674"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Unity Biotechnology" id="1119259"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Guangzhou Virotech Pharmaceutical Co Ltd" id="1120369"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Quick Biology Inc" id="1126950"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alphabet Inc" id="1129360"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bioventures LLC" id="1151752"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Abbott Laboratories" id="13601"/><CountAsOwner>21</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>22</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bayer AG" id="14455"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BD Technologies" id="14596"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Celgene Corp" id="15331"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gilead Sciences Inc" id="16450"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sumitomo Chemical Co Ltd" id="20268"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="US Government" id="20516"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Case Western Reserve University" id="20553"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Cincinnati" id="20555"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Rijksuniversiteit te Groningen" id="20581"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johns Hopkins University" id="20596"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Washington" id="20701"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Yeshiva University" id="20704"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Whitehead Institute for Biomedical Research" id="20939"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Walter and Eliza Hall Institute of Medical Research" id="21082"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mayo Clinic Foundation" id="21111"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>9</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>9</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="St Jude Children's Research Hospital" id="21814"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Georgetown University" id="22821"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Agenus Inc" id="23221"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard Medical School" id="24839"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>3</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Xi' An Medical University" id="25216"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cincinnati Children's Hospital Medical Center" id="25631"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Washington University in St Louis" id="26113"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Samsung Electronics Co Ltd" id="28039"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Infinity Pharmaceuticals Inc" id="29753"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Buck Institute" id="30209"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wuhan University" id="CM28029"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="UNIVERSIDAD POLITECNICA DE VALENCIA" id="CM28045"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>